NEW YORK (GenomeWeb News) - William Rapeport has joined the board of directors at Galapagos. Rapeport is currently CEO at RespiVert and he is an honorary principal research fellow at the UK’s National Heart & Lung Institute at the Imperial College School of Medicine. has joined the board of directors at . Rapeport is currently CEO at and he is an honorary principal research fellow at the at the .
Rapeport worked in new compound development at Pfizer Central Research and he was a worldwide director of clinical pharmacology at GlaxoWellcome.He subsequently served as senior VP for the Centre of Excellence in Respiratory and Inflammatory Diseases at GlaxoSmithKline. Rapeport’s term with the board of directors lasts until the 2009 shareholder’s meeting.
Gene Cartwright, formerly president of GE Healthcare’s molecular diagnostics business, has been named CEO of Omnyx, a newly formed joint venture between GE Healthcare and the University of Pittsburgh Medical Center. The new JV will develop and sell advanced digital imaging systems for pathologists.
Cartwright joined GE Healthcare in late 2005 from Abbott Laboratories, where he served as vice-president of strategic programs for its molecular diagnostics business.
InforSense has named David Bennett executive VP of worldwide sales. Bennett formerly directed SeeBeyond’s Europe, Middle East, and Africa businesses, and he was an international sales manager at the company. He also has held varying sales positions at Ingres, the ASK Group, Wang Laboratories, and Unilever.
Alexander Makarov, who is director of global research for life sciences mass spectrometry at Thermo Fisher Scientific, has received the 2008 Distinguished Contribution in Mass Spectrometry Award from the American Society for Mass Spectrometry.
Makarov was a research fellow at the University of Warwick, Coventry, UK, and he was a senior scientific researcher at the Russian Academy of Sciences in Moscow.
Wayne Marshall has resigned from his position as CEO and president at GeneNews and has shifted into the role of chief clinical scientist and vice chair of the company’s board of directors. Marshall has appointed three independent directors to begin the search for a new leader. Until the company finds a new CEO, fellow independent director Heiner Dreismann will oversee the company’s business as lead director.
Stratagem IPM has appointed David Roberts to the post of chairman, a job he will take over from the retiring chairman, Laurence Jenkins. Roberts was senior VP and global head of intellectual property at GlaxoSmithKline. He also is a non-executive director on the steering board of the UK IP Office.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.